Century Therapeutics Inc
IPSCHealthcare·Biotechnology·USA·Micro·NASD·Nov 12 • 3:59 PM ET
1.63-0.11 (-6.32%)
2026-11-13 13:44 CET
Market cap
$295.15M
Revenue, TTM
0.00 USD m
Net income, TTM
-98.82 USD m
Free cash flow, TTM
-85.06 USD m
EPS diluted, TTM
-0.61
Price
IPSC against its 20, 50 and 200-day averagesPatternshover a marker to name it
46.4% under the 52-week high of 3.04 on 10 Mar 2026. 52-week low 0.44 on 17 Nov 2025. Last 15 sessions, 38.7% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 45
CANSLIM 4 of 6 — fails: EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 1 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Zanger 1 of 5 — fails: Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 2 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200
Accumulation 3 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200
Relative Strength 2 of 3 — fails: 200-Day Simple Moving Average: Price above SMA200
Profile
IPSC52-week range, 46% of the way up
0.443.04
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
| Index | RUT |
|---|---|
| Employees | 78 |
| IPO | Jun 18, 2021 |
| Beta | 1.76 |
| ATR, 14d | 0.16 |
| Rel volume | 0.00 |
| Short float | 26.04% |
| Insider own | 32.08% |
| Inst own | 66.36% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $295.15M |
| Enterprise Value | 215.44M |
| Income | -98.82M |
| Sales | 0.00M |
| Book / share | 1.16 |
| Cash / share | 0.65 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 78 |
| IPO | Jun 18, 2021 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 1.41 |
| Price / cash | 2.52 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 8.74 |
| Current Ratio | 8.74 |
| Debt / equity | 0.18 |
| Long-term debt / equity | 0.16 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.61 |
|---|---|
| Earnings next year | -0.44 |
| Earnings next quarter | -0.12 |
| Earnings this year | -270.00% |
| Earnings next year | 15.70% |
| Earnings growth, 5 years | - |
| Past earnings growth | 63.45% 35.31% |
| Past sales growth | 175.88% - |
| Earnings vs last year | -219.52% |
| Sales vs last year | -100.00% |
| Earnings vs last quarter | 71.46% |
| Sales vs last quarter | - |
| Earnings | Nov 12 BMO |
| Surprise | 8.33% - |
Ownership
| Insiders own | 32.08% |
|---|---|
| Insider trades | -0.02% |
| Institutions own | 66.36% |
| Institution trades | 11.12% |
| Return on assets | -38.96% |
| Return on equity | -51.16% |
| Return on capital | -40.56% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | 4.65% |
| 50-day average | -1.39% |
| 200-day average | -21.09% |
Technical
| Shares out | 181.24M |
|---|---|
| Shares floating | 122.98M |
| Short / float | 26.04% |
| Short ratio | 44.57 |
| Short interest | 32.03M |
| 52-week high | 3.04 -46.4% |
| 52-week low | 0.44 +274.7% |
| Volatility | 12.54% 11.58% |
| Average range | 0.16 |
| Strength index | 51.39 |
| Market sensitivity | 1.76 |
| Relative volume | 0.00 |
| Avg Volume | 718.55K |
| Volume | 0 |
Performance
| Perf Week | 7.95% |
|---|---|
| Perf Month | 18.12% |
| Perf Quarter | -15.10% |
| Perf Half Y | -31.51% |
| Perf YTD | 63.85% |
| Perf Year | 189.37% |
| Perf 3Y | 26.36% |
| Perf 5Y | -92.18% |
| Perf 10Y | - |
| Recommendation | 1.33 |
| Target Price | 5.12 |
| Prev Close | 1.63 |
| Price | 1.63 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 12| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| May 27, 2026 | Initiated | Mizuho | Outperform | $8 | +390.8% |
| Feb 25, 2026 | Initiated | TD Cowen | Buy | ||
| Aug 08, 2024 | Initiated | Rodman & Renshaw | Buy | $6 | +268.1% |
| Aug 28, 2023 | Downgrade | JP Morgan | Overweight → Neutral | $28 → $5 | +206.7% |
| Dec 27, 2022 | Initiated | Chardan Capital Markets | Buy | $19 | +1,065.6% |
| Oct 31, 2022 | Initiated | Guggenheim | Buy | $15 | +820.2% |
| Oct 10, 2022 | Initiated | Canaccord Genuity | Buy | $28 | +1,617.8% |
| May 23, 2022 | Initiated | H.C. Wainwright | Buy | $27 | +1,556.4% |
| May 12, 2022 | Initiated | William Blair | Mkt Perform | ||
| Jul 13, 2021 | Initiated | Piper Sandler | Overweight | $38 | +2,231.3% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| SANA | Sana Biotechnology Inc | 620.25M |
| FATE | Fate Therapeutics Inc | 162.90M |
| VRTX | Vertex Pharmaceuticals Inc | 137.57B |
| CABA | Cabaletta Bio Inc | 284.82M |
| KYTX | Kyverna Therapeutics Inc | 309.21M |
| ALLO | Allogene Therapeutics Inc | 301.46M |
| NKTX | Nkarta Inc | 91.79M |
| CRBU | Caribou Biosciences Inc | 41.18M |
| CRSP | CRISPR Therapeutics AG | 4.16B |
| SNY | Sanofi ADR | 115.57B |
Insider trading
latest 14 of 34| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Carr Douglas | SVP Finance & Operations | Nov 03 '26 | Sale | 1.52 | 266 | 404 | 502,641 | Nov 05 04:10 PM |
| Carr Douglas | Officer | Nov 03 '26 | Proposed Sale | 1.52 | 266 | 404 | Nov 03 03:32 PM | |
| Russotti Gregory | See Remarks | Sep 14 '26 | Sale | 1.93 | 2,587 | 4,993 | 509,198 | Sep 15 06:25 PM |
| Carr Douglas | SVP Finance & Operations | Sep 14 '26 | Sale | 1.93 | 1,658 | 3,200 | 502,907 | Sep 15 06:25 PM |
| Russotti Gregory | Officer | Sep 14 '26 | Proposed Sale | 1.93 | 2,587 | 4,994 | Sep 14 03:31 PM | |
| Carr Douglas | Officer | Sep 14 '26 | Proposed Sale | 1.93 | 1,658 | 3,201 | Sep 14 03:29 PM | |
| Russotti Gregory | See Remarks | Sep 08 '26 | Sale | 2.05 | 534 | 1,095 | 511,785 | Sep 09 04:35 PM |
| Carr Douglas | SVP Finance & Operations | Sep 08 '26 | Sale | 2.05 | 254 | 521 | 504,565 | Sep 09 04:34 PM |
| Russotti Gregory | Officer | Sep 08 '26 | Proposed Sale | 2.05 | 534 | 1,094 | Sep 08 03:10 PM | |
| Carr Douglas | SVP Finance & Operations | Aug 03 '26 | Sale | 1.98 | 275 | 544 | 504,819 | Aug 05 04:08 PM |
| Russotti Gregory | See Remarks | Jun 12 '26 | Sale | 2.23 | 2,584 | 5,767 | 512,319 | Jun 15 07:57 PM |
| Carr Douglas | SVP Finance & Operations | Jun 12 '26 | Sale | 2.23 | 1,654 | 3,692 | 505,094 | Jun 15 07:56 PM |
| Russotti Gregory | Officer | Jun 12 '26 | Proposed Sale | 2.23 | 2,584 | 5,768 | Jun 12 03:35 PM | |
| Russotti Gregory | See Remarks | Jun 08 '26 | Sale | 2.11 | 524 | 1,106 | 514,903 | Jun 09 04:10 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| OMFS | Invesco Russell 2000 Dynamic Multifactor ETF | AUM: 265.58M |
| AVSC | Avantis U.S Small Cap Equity ETF | AUM: 3.33B |
| FESM | Fidelity Enhanced Small Cap Core ETF | AUM: 6.90B |
| VHT | Vanguard Health Care ETF | AUM: 21.54B |
News
latest 14 of 200- Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates (GlobeNewswire) -6.32%
- Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
- Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 (GlobeNewswire)
- Century Therapeutics Appoints Joseph Truitt to Board of Directors (GlobeNewswire)
- Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates (GlobeNewswire)
- Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D Clinical & Research Congress 2026 (GlobeNewswire)
- New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 (GlobeNewswire)
- Century Therapeutics Reports First Quarter Financial Results and Business Updates (GlobeNewswire)
- Century Therapeutics Selected for Oral Presentation of CNTY-813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions (GlobeNewswire)
- Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates (GlobeNewswire) -8.42%
- Century Therapeutics to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
- Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission (Insider Monkey) -5.47%
- Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +13.24%
- Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes (GlobeNewswire) +36.15%
Quarterly earnings
2026Q3 EPS -0.110 beat -0.120, from -0.400 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-12 08:30 | -0.110 | -0.120 | -0.114 | 0.00 | 0.00 | EPS -8.3% · sales - | vs 2025Q3, year-ago quarter · EPS -72.5% · sales - | 5 | Open +0.57% vs SPY -0.77%. Close -6.32% vs SPY -0.35% |
| 2026Q2ended 2026-06-30 | 2026-08-12 08:30 | -0.170 | -0.110 | -0.168 | 0.00 | 0.00 | EPS +54.5% · sales - | vs 2025Q2, year-ago quarter · EPS -55.3% · sales - | 5 EPS · 4 sales | Open +0.97% vs SPY +0.54%. Close -4.85% vs SPY +0.25% |
| 2026Q1ended 2026-03-31 | 2026-05-13 08:30 | -0.110 | -0.158 | -0.112 | 0.00 | 0.00 | EPS -30.4% · sales - | vs 2025Q1, year-ago quarter · EPS -112.4% · sales -100.0% | 5 | Open +0.44% vs SPY +0.04%. Close -0.44% vs SPY +0.56% |
| 2025Q4ended 2025-12-31 | 2026-03-12 08:30 | -0.250 | -0.290 | -0.219 | 0.00 | 0.00 | EPS -13.8% · sales - | vs 2024Q4, year-ago quarter · EPS -39.0% · sales -100.0% | 4 | Open +6.23% vs SPY -0.76%. Close -8.42% vs SPY -1.52% |
| 2025Q3ended 2025-09-30 | 2025-11-13 08:30 | -0.400 | -0.338 | -0.398 | 0.00 | 0.00 | EPS +18.5% · sales - | vs 2024Q3, year-ago quarter · EPS +8.1% · sales -100.0% | 4 | Open -5.89% vs SPY -0.42%. Close -17.54% vs SPY -1.66% |
| 2025Q2ended 2025-06-30 | 2025-08-14 16:30 | -0.380 | -0.376 | -0.377 | 0.00 | 0.00 | EPS +1.0% · sales - | vs 2024Q2, year-ago quarter · EPS 0.0% · sales -100.0% | 6 EPS · 5 sales | Open +4.22% vs SPY +0.16%. Close +2.15% vs SPY -0.23% |
| 2025Q1ended 2025-03-31 | 2025-05-15 16:30 | 0.890 | -0.008 | 0.889 | 109.16 | 41.29 | EPS -11510.3% · sales +164.4% | vs 2024Q1, year-ago quarter · EPS -297.8% · sales +12667.7% | 7 EPS · 6 sales | Open 0.00% vs SPY +0.13%. Close +8.23% vs SPY +0.63% |
| 2024Q4ended 2024-12-31 | 2025-03-19 16:30 | -0.410 | -0.410 | -0.425 | 4.18 | 0.78 | EPS 0.0% · sales +432.8% | vs 2023Q4, year-ago quarter · EPS -37.9% · sales +1477.0% | 7 | Open -1.54% vs SPY -0.67%. Close -5.66% vs SPY -0.29% |
| 2024Q3ended 2024-09-30 | 2024-11-05 08:30 | -0.370 | -0.451 | -0.369 | 0.79 | 0.44 | EPS -17.9% · sales +79.8% | vs 2023Q3, year-ago quarter · EPS -32.7% · sales +434.5% | 5 | Open 0.00% vs SPY +0.16%. Close +5.56% vs SPY +1.21% |
| 2024Q2ended 2024-06-30 | 2024-08-08 08:30 | -0.380 | -0.455 | -0.380 | 0.77 | 0.43 | EPS -16.4% · sales +79.3% | vs 2023Q2, year-ago quarter · EPS -32.1% · sales +678.8% | 5 | Open +4.05% vs SPY +1.01%. Close +4.05% vs SPY +2.31% |
| 2024Q1ended 2024-03-31 | 2024-05-09 08:30 | -0.450 | -0.513 | -0.451 | 0.86 | 0.21 | EPS -12.3% · sales +307.1% | vs 2023Q1, year-ago quarter · EPS -15.1% · sales -50.3% | 5 | Open +0.65% vs SPY +0.04%. Close -0.98% vs SPY +0.58% |
| 2023Q4ended 2023-12-31 | 2024-03-14 08:30 | -0.660 | -0.548 | -0.658 | 0.27 | 1.67 | EPS +20.5% · sales -84.1% | vs 2022Q4, year-ago quarter · EPS +22.2% · sales -49.1% | 7 | Open -0.41% vs SPY +0.19%. Close -7.20% vs SPY -0.20% |
| 2023Q3ended 2023-09-30 | 2023-11-09 08:30 | -0.550 | -0.521 | -0.550 | 0.15 | 1.32 | EPS +5.5% · sales -88.8% | vs 2022Q3, year-ago quarter · EPS +3.8% · sales -93.3% | 8 | - |
| 2023Q2ended 2023-06-30 | 2023-08-09 08:30 | -0.560 | -0.544 | -0.562 | 0.10 | 1.14 | EPS +3.0% · sales -91.3% | vs 2022Q2, year-ago quarter · EPS +3.7% · sales -92.9% | 8 | - |
| 2023Q1ended 2023-03-31 | 2023-05-11 08:30 | -0.530 | -0.524 | -0.533 | 1.72 | 1.47 | EPS +1.2% · sales +16.7% | vs 2022Q1, year-ago quarter · EPS -19.7% · sales +62.6% | 9 EPS · 8 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-17 16:30 | -0.540 | -0.582 | -0.543 | 0.52 | 2.00 | EPS -7.2% · sales -74.0% | vs 2021Q4, year-ago quarter · EPS +5.9% · sales - | 10 | - |
Annual earnings
2025FY EPS -0.140 beat -0.180, from -1.610 a year earlier. Sales 109.16 missed 109.18, from 6.59 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.353 | - | - | 43.00 | - |
| 2029FYestimate | - | -0.380 | - | - | 0.00 | - |
| 2028FYestimate | - | -0.360 | - | - | 0.00 | - |
| 2027FYestimate | - | -0.437 | - | - | 0.00 | - |
| 2026FYestimate | - | -0.518 | - | - | 0.00 | - |
| 2025FY | -0.140 | -0.180 | -0.125 | 109.16 | 109.18 | - |
| 2024FY | -1.610 | -1.616 | -1.609 | 6.59 | 3.19 | - |
| 2023FY | -2.300 | -2.172 | -2.304 | 2.24 | 3.65 | - |
| 2022FY | -2.270 | -2.308 | -2.267 | 5.20 | 6.69 | - |
| 2021FY | -2.960 | -3.215 | -1.742 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier. 2025Q1 operating margin 67.7%, from -3,684% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -0.52 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-12 | -0.52 | -1.1% |
| 2026Q4 | E | per share | 2026-11-12 | -0.12 | -4.8% |
| 2026FY | R | per share | 2026-11-12 | -0.52 | -2.8% |
| 2026Q4 | R | per share | 2026-11-12 | -0.12 | -7.7% |
| 2026Q4 | S | per share | 2026-11-12 | 0.00 | - |
| 2026Q3 | E | per share | 2026-10-26 | -0.12 | 0.0% |
| 2026Q3 | R | per share | 2026-10-26 | -0.12 | 0.0% |
| 2026FY | S | per share | 2026-08-12 | 0.00 | - |
| 2026Q3 | S | per share | 2026-08-12 | 0.00 | - |
| 2026Q2 | E | per share | 2026-08-01 | -0.11 | 0.0% |
| 2026Q2 | R | per share | 2026-07-27 | -0.12 | 0.0% |
| 2026Q2 | S | per share | 2026-06-20 | 0.00 | - |
| 2026Q1 | E | per share | 2026-04-20 | -0.16 | +10.9% |
| 2026Q1 | S | per share | 2026-04-20 | 0.00 | - |
| 2026Q1 | R | per share | 2026-03-12 | -0.22 | +4.8% |
| 2025FY | E | per share | 2026-02-24 | -0.18 | +14.9% |
| 2025Q4 | E | per share | 2026-02-24 | -0.29 | +8.7% |
| 2025FY | R | per share | 2026-02-24 | -0.20 | +39.3% |
| 2025Q4 | R | per share | 2026-02-24 | -0.31 | +22.0% |
| 2025Q4 | S | per share | 2026-02-24 | 0.00 | - |
| 2025FY | S | - | 2026-02-24 | 109.18 | +0.0% |
| 2025Q3 | E | per share | 2025-10-29 | -0.34 | 0.0% |
| 2025Q3 | R | per share | 2025-09-02 | -0.19 | -42.4% |
| 2025Q3 | S | per share | 2025-09-02 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-06 | -0.38 | -0.9% |
| 2025Q2 | S | per share | 2025-08-06 | 0.00 | - |
| 2025Q2 | R | per share | 2025-07-30 | -0.37 | 0.0% |
| 2025Q1 | E | per share | 2025-05-01 | -0.01 | +9.9% |
| 2025Q1 | S | per share | 2025-04-23 | 41.29 | +16.2% |
| 2025Q1 | R | per share | 2025-03-20 | -0.07 | -82.5% |
| 2024FY | E | per share | 2025-03-19 | -1.62 | 0.0% |
| 2024Q4 | E | per share | 2025-03-19 | -0.43 | 0.0% |
| 2024FY | S | per share | 2025-03-19 | 3.11 | 0.0% |
| 2024Q4 | S | per share | 2025-03-19 | 0.67 | 0.0% |
| 2024FY | R | per share | 2025-02-25 | -0.09 | -88.3% |
| 2024Q4 | R | per share | 2025-02-12 | 0.93 | - |
| 2024Q3 | E | per share | 2024-10-28 | -0.45 | 0.0% |
| 2024Q3 | S | per share | 2024-10-22 | 0.44 | 0.0% |
| 2024Q2 | E | per share | 2024-07-24 | -0.45 | 0.0% |
| 2024Q2 | S | per share | 2024-07-24 | 0.43 | 0.0% |
| 2024Q1 | E | per share | 2024-03-15 | -0.51 | -0.2% |
| 2024Q1 | S | per share | 2024-03-14 | 0.21 | -1.2% |
| 2023FY | E | per share | 2024-03-13 | -2.17 | +3.8% |
| 2023FY | S | per share | 2024-03-13 | 3.65 | -4.7% |
| 2023FY | R | per share | 2024-02-08 | -2.13 | -1.8% |
Estimate history
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -4.465 | -0.977 | -1.742 | -2.267 | -2.304 | -1.609 | -0.111 | -0.6124 | - |
| Sales USD millions | 0 | 0 | 0 | 5 | 2 | 7 | 109 | 0 | - |
| Shares million shares | 55 | 55 | 55 | 58 | 60 | 86 | 88 | - | 181 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.369 | -0.425 | 0.889 | -0.377 | -0.398 | -0.219 | -0.112 | -0.168 | -0.114 |
| Sales USD millions | 1 | 4 | 109 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 85 | 86 | 86 | 86 | 87 | 88 | 180 | 181 | 181 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 109.16+1556.4% | 6.59+195.5% | 2.23-57.1% | 5.20 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 11.35 | 13.10-1.5% | 13.30+2.0% | 13.04+29.5% | 10.07+119.9% | 4.58+161.7% | 1.75+600.0% | 0.25 |
| Gross Profit | -11.35 | 96.06 | -6.71 | -10.81 | -4.87 | -4.58 | -1.75 | -0.25 |
| Selling, General and Administrative Excl. Other | 92.24 | 111.10-12.9% | 127.56+11.5% | 114.37-3.9% | 118.96+31.7% | 90.30+90.4% | 47.42+139.7% | 19.78 |
| Research and Development | 63.10 | 82.57-23.0% | 107.24+15.7% | 92.71-4.6% | 97.17+28.4% | 75.65+90.7% | 39.68+178.1% | 14.27 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -103.60 | -15.04 | -134.27 | -125.18 | -123.83 | -94.88 | -49.18 | -20.03 |
| Interest Expense | 0.00 | 0.00 | 0.00-100.0% | 0.54-62.2% | 1.43+12.6% | 1.27+234.2% | 0.38 | 0.00 |
| Unusual Expense | 2.47 | 2.23-42.4% | 3.87-81.9% | 21.36+113.6% | 10.00 | 0.00-100.0% | 4.72-97.9% | 225.95 |
| Net Income Before Taxes | -98.89 | -9.65 | -124.78 | -134.79 | -130.84 | -95.78 | -53.58 | -244.77 |
| Income Taxes | -0.07 | -0.07-103.9% | 1.79-4.8% | 1.88+1988.9% | 0.09+125.0% | 0.04 | 0.00 | 0.00 |
| Consolidated Net Income | -98.82 | -9.58 | -126.57 | -136.67 | -130.93 | -95.82 | -53.58 | -244.77 |
| Net Income From Continuing Operations | -98.82 | -9.58 | -126.57 | -136.67 | -130.93 | -95.82 | -53.58 | -244.77 |
| Net Income | -98.82 | -9.58 | -126.57 | -136.67 | -130.93 | -95.82 | -53.58 | -244.77 |
| EPS (Recurring) per share | -0.47 | -0.09 | -1.57 | -2.05 | -2.15 | -1.74 | -0.92 | -1.58 |
| EPS (Basic, Before Extraordinaries) per share | -0.61 | -0.11 | -1.61 | -2.30 | -2.27 | -1.74 | -0.98 | -4.46 |
| EPS (Diluted) per share | -0.61 | -0.11 | -1.61 | -2.30 | -2.27 | -1.74 | -0.98 | -4.46 |
| EBITDA | -92.24 | -1.94 | -120.97 | -112.14 | -113.76 | -90.30 | -47.42 | -19.78 |
| Non-Operating Income (Expense) | 7.18 | 7.62-43.0% | 13.36+8.7% | 12.29+178.1% | 4.42+1063.2% | 0.38-45.7% | 0.70-42.1% | 1.21 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 5.87 | 5.40-46.1% | 10.02-13.2% | 11.55+37.0% | 8.43+147.9% | 3.40+286.4% | 0.88+486.7% | 0.15 |
| Price To Sales Ratio ratio | - | 0.79 | 12.06 | 88.11 | 56.99 | - | - | - |
| Gross Margin % | - | 88.00 | -101.91 | -483.62 | -93.71 | - | - | - |
| Operating Margin % | - | -13.78 | -2,037.81 | -5,600.94 | -2,381.82 | - | - | - |
| Net Margin % | - | -8.78 | -1,920.87 | -6,115.12 | -2,518.41 | - | - | - |
| Shares Outstanding million shares | 181.24 | 87.52+2.0% | 85.84+42.3% | 60.34+3.2% | 58.47+6.3% | 55.01+0.3% | 54.820.0% | 54.82 |
| Market Capitalization | 295.15 | 295.15+243.7% | 85.88-56.8% | 198.65-34.3% | 302.54-65.1% | 866.61+3.5% | 837.65 | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 109.16+12742.4% | 4.17+1444.4% |
| Cost of Goods Sold Incl. D&A | 2.19-30.0% | 2.62-18.1% | 3.00-6.8% | 3.55+6.9% | 3.13-5.2% | 3.20-7.5% | 3.22-0.3% | 3.32-6.5% |
| Gross Profit | -2.19 | -2.62 | -3.00-102.8% | -3.55-517.6% | -3.13 | -3.20 | 105.94 | 0.85 |
| Selling, General and Administrative Excl. Other | 23.02-11.4% | 24.71-20.5% | 22.50-29.7% | 22.02-35.3% | 25.99-20.3% | 31.08-5.4% | 32.01+10.6% | 34.06+24.6% |
| Research and Development | 15.88-18.1% | 16.98-28.2% | 14.10-39.6% | 16.14-38.1% | 19.40-18.9% | 23.66-0.4% | 23.36+15.6% | 26.06+16.9% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -25.21 | -27.32 | -25.50-134.5% | -25.57 | -29.12 | -34.28 | 73.94 | -33.20 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00-100.0% | 9.21+2323.7% | -1.82 | -4.92-220.6% | 7.00 | 0.38 | -0.24 | 4.08-68.9% |
| Net Income Before Taxes | -23.45 | -34.55 | -21.64-128.3% | -19.24 | -34.42 | -32.54 | 76.56 | -34.30 |
| Income Taxes | 0.00 | 0.00 | 0.00 | -0.07-103.9% | 0.00 | 0.00-100.0% | 0.00 | 1.78 |
| Consolidated Net Income | -23.45 | -34.55 | -21.64-128.3% | -19.17 | -34.42 | -32.54 | 76.56 | -36.07 |
| Net Income From Continuing Operations | -23.45 | -34.55 | -21.64-128.3% | -19.17 | -34.42 | -32.54 | 76.56 | -36.07 |
| Net Income | -23.45 | -34.55 | -21.64-128.3% | -19.17 | -34.42 | -32.54 | 76.56 | -36.07 |
| EPS (Recurring) per share | -0.11 | -0.14 | -0.12-113.5% | -0.26 | -0.34 | -0.37 | 0.89 | -0.39 |
| EPS (Basic, Before Extraordinaries) per share | -0.11 | -0.17 | -0.11-112.4% | -0.22 | -0.40 | -0.38 | 0.89 | -0.42 |
| EPS (Diluted) per share | -0.11 | -0.17 | -0.11-112.4% | -0.22 | -0.40 | -0.38 | 0.89 | -0.42 |
| EBITDA | -23.02 | -24.71 | -22.50-129.2% | -22.02 | -25.99 | -31.08 | 77.16 | -29.88 |
| Non-Operating Income (Expense) | 1.75+2.9% | 1.98-6.6% | 2.04-14.3% | 1.41-52.8% | 1.70-52.2% | 2.12-40.6% | 2.38-26.8% | 2.99-14.6% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.44+61.8% | 1.95-12.2% | 1.45-24.5% | 1.03-51.0% | 0.89-66.0% | 2.22-19.9% | 1.92-24.1% | 2.10-25.3% |
| Price To Sales Ratio ratio | - | - | - | 0.80 | 0.38 | 0.42 | 0.36 | 13.02 |
| Gross Margin % | - | - | - | - | - | - | 97.05 | 20.49 |
| Operating Margin % | - | - | - | - | - | - | 67.73 | -795.64 |
| Net Margin % | - | - | - | - | - | - | 70.13 | -864.44 |
| Shares Outstanding million shares | 181.24+109.5% | 180.55+109.2% | 180.10+109.1% | 87.52+2.0% | 86.53+2.1% | 86.32+2.1% | 86.15+32.9% | 85.84+42.3% |
| Market Capitalization | 295.15+586.1% | 441.87+817.9% | 406.17+891.6% | 86.95+1.2% | 43.02-70.3% | 48.14-77.7% | 40.96-84.9% | 85.88-56.8% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 117.91-37.7% | 189.29+9.6% | 172.74-45.2% | 315.50+41.6% | 222.88+191.2% | 76.54-6.1% | 81.54 |
| Short Term Receivables | 0.67-55.9% | 1.52+126.9% | 0.67-14.1% | 0.78+212.0% | 0.25 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 2.19-32.4% | 3.24-9.7% | 3.59+4.4% | 3.44-31.6% | 5.03+122.6% | 2.26-12.4% | 2.58 |
| Total Current Assets | 120.77-37.8% | 194.05+9.6% | 176.99-44.6% | 319.72+40.1% | 228.15+189.5% | 78.80-6.3% | 84.12 |
| Net Property, Plant & Equipment | 66.17-27.2% | 90.85-1.3% | 92.08-17.6% | 111.73+60.0% | 69.82+181.8% | 24.78+895.2% | 2.49 |
| Total Investments and Advances | 2.36-93.0% | 33.59-63.1% | 91.08+69.2% | 53.83-60.9% | 137.63+5910.0% | 2.29-43.9% | 4.08 |
| Long-Term Note Receivable | - | - | - | - | 0.00-100.0% | 31.90-54.4% | 70.00 |
| Intangible Assets | 34.200.0% | 34.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.21-60.4% | 0.53-1.9% | 0.54-57.1% | 1.26-28.8% | 1.77+94.5% | 0.91+333.3% | 0.21 |
| Total Assets | 223.70-36.7% | 353.22-2.1% | 360.69-25.9% | 486.54+11.2% | 437.38+215.4% | 138.68-13.8% | 160.90 |
| Short Term Debt Incl. Current Port. of LT Debt | 3.32-31.8% | 4.87+222.5% | 1.51-78.4% | 6.98+323.0% | 1.65+587.5% | 0.24 | 0.00 |
| Accounts Payable | 4.77+54.9% | 3.08+12.4% | 2.74-49.7% | 5.45-28.3% | 7.60 | 0.00 | 0.00 |
| Other Current Liabilities | 12.13-90.0% | 121.84+796.5% | 13.59-21.9% | 17.39+171.3% | 6.41-46.0% | 11.87+297.0% | 2.99 |
| Total Current Liabilities | 20.23-84.4% | 129.78+627.1% | 17.85-40.1% | 29.82+90.5% | 15.65+29.2% | 12.11+305.0% | 2.99 |
| Long Term Debt | 40.24-17.8% | 48.96+4.9% | 46.66+9.9% | 42.44+80.9% | 23.46+10.0% | 21.32 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 4.30-1.6% | 4.37 | - | - | - | - | - |
| Other Liabilities | 0.00-100.0% | 8.74-92.2% | 111.44-0.1% | 111.55+5422.3% | 2.02 | 0.00 | 0.00 |
| Total Liabilities | 64.77-66.2% | 191.85+9.0% | 175.94-4.3% | 183.81+346.8% | 41.14+23.1% | 33.43+1018.1% | 2.99 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 179.760.0% | 179.76 |
| Common Equity | 158.94-1.5% | 161.36-12.7% | 184.75-39.0% | 302.74-23.6% | 396.24 | -74.51 | -21.86 |
| Total Shareholders Equity | 158.94-1.5% | 161.36-12.7% | 184.75-39.0% | 302.74-23.6% | 396.24+276.5% | 105.25-33.3% | 157.90 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 158.94-1.5% | 161.36-12.7% | 184.75-39.0% | 302.74-23.6% | 396.24+276.5% | 105.25-33.3% | 157.90 |
| Total Liabilities & Stockholders Equity | 223.70-36.7% | 353.22-2.1% | 360.69-25.9% | 486.54+11.2% | 437.38+215.4% | 138.68-13.8% | 160.90 |
| Book Value Per Share per share | 1.82-3.2% | 1.88-38.6% | 3.06-40.9% | 5.18-28.1% | 7.20 | -1.36 | -0.40 |
| Tangible Book Value Per Share per share | 1.43-3.4% | 1.48-51.6% | 3.06-40.9% | 5.18-28.1% | 7.20 | -1.36 | -0.40 |
| Full-Time Employees people | 78-48.0% | 150-9.1% | 165+1.2% | 163-4.1% | 170+58.9% | 107-50.0% | 214 |
| Price to Book Ratio ratio | 1.27 | 0.44 | 0.90 | 0.90 | 2.20 | 1.98 | - |
| Return on Assets % | -3.32 | -35.46 | -32.26 | -28.34 | -33.27 | -35.77 | - |
| Return on Equity % | -5.98 | -73.14 | -56.07 | -37.46 | -38.22 | -40.72 | - |
| Return on Invested Capital % | -4.81 | -60.18 | -59.06 | -37.93 | -22.83 | -42.33 | -155.01 |
| Quick Ratio ratio | 5.97 | 1.50 | 9.92 | 10.72 | 14.57 | 6.51 | 28.10 |
| Current Ratio ratio | 5.97 | 1.50 | 9.92 | 10.72 | 14.57 | 6.51 | 28.10 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -98.82 | -9.58 | -126.57 | -136.67 | -130.93 | -95.82 | -53.58 | -244.77 |
| Depreciation | 11.35 | 13.10-1.5% | 13.30+2.0% | 13.04+29.5% | 10.07+119.9% | 4.58+161.7% | 1.75+600.0% | 0.25 |
| Other Funds (Non Cash) | 9.19 | 7.23-37.3% | 11.54-55.4% | 25.90+136.1% | 10.97+117.7% | 5.04-11.4% | 5.69-97.5% | 226.09 |
| Funds from Operations | -78.35 | 10.68 | -100.86 | -97.73 | -109.89 | -86.20 | -46.13 | -18.43 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -5.03 | -114.55 | -9.28-201.3% | 9.16-92.6% | 123.44 | -3.58-173.7% | 4.86+115.0% | 2.26 |
| Cash from Operating Activities | -83.38 | -103.88 | -110.14 | -88.57-753.7% | 13.55 | -89.79 | -41.27 | -16.17 |
| Capital Expenditures | -1.67 | -0.85 | -0.15 | -13.74 | -30.60 | -44.97 | -9.82 | -2.46 |
| Net Assets From Acquisitions | 0.00 | 0.00 | -9.61 | 0.00 | 0.00 | 0.00 | -4.72 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 24.17 |
| Purchase or Sale of Investments | -53.35 | 108.35+89.3% | 57.24-23.5% | 74.87+328.3% | 17.48 | -253.37 | -8.21 | -41.54 |
| Purchase of Investments | -173.57 | -51.17 | -119.55 | -209.03 | -254.00 | -330.03 | -49.86 | -41.54 |
| Sale Or Maturity of Investments | 120.22 | 159.52-9.8% | 176.79-37.7% | 283.90+4.6% | 271.48+254.1% | 76.67+84.1% | 41.65 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -54.96 | 107.50+126.4% | 47.48-22.3% | 61.13 | -13.13 | -298.34 | -22.76 | -19.83 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 127.06 | 0.17-99.8% | 74.56+14238.5% | 0.52-98.1% | 27.16-92.9% | 383.55 | 0.00-100.0% | 74.84 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 127.06 | 0.17-99.8% | 74.56+14238.5% | 0.52-98.1% | 27.16-92.9% | 383.55 | 0.00-100.0% | 74.84 |
| Proceedsfrom Stock Options | 126.39 | 0.00-100.0% | 74.42+14211.5% | 0.52-98.1% | 27.16-92.9% | 381.24 | 0.00-100.0% | 74.84 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | -10.24 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | -10.24 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | -10.24 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 34.23-28.4% | 47.83 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 127.06 | 0.17-99.8% | 74.56 | -9.72-135.8% | 27.16-93.5% | 417.77+776.0% | 47.69-36.3% | 74.84 |
| Net Change in Cash | -11.28 | 3.80-68.1% | 11.91 | -37.16-234.7% | 27.58-7.0% | 29.65 | -16.34-142.1% | 38.84 |
| Free Cash Flow | -85.06 | -104.72 | -110.29 | -102.30 | -17.05 | -134.76 | -51.09 | -18.63 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Deferred Taxes & Investment Tax Credit | - | -0.07-108.0% | 0.87 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 117.20-11.7% | 119.71-23.2% | 135.15-18.2% | 117.91-37.7% | 132.75-33.0% | 155.84-20.7% | 165.12-14.0% | 189.29+9.6% |
| Short Term Receivables | 1.20+150.0% | 1.48+134.9% | 1.37+39.8% | 0.67-55.9% | 0.48-64.4% | 0.63-64.2% | 0.98 | 1.52+126.9% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 4.31-3.8% | 3.58-3.2% | 2.51-28.9% | 2.19-32.4% | 4.48-31.6% | 3.70-30.5% | 3.53-54.7% | 3.24-9.7% |
| Total Current Assets | 122.71-10.9% | 124.77-22.1% | 139.04-18.0% | 120.77-37.8% | 137.71-33.2% | 160.17-21.3% | 169.63-15.1% | 194.05+9.6% |
| Net Property, Plant & Equipment | 46.23-34.2% | 47.99-43.1% | 68.58-21.9% | 66.17-27.2% | 70.28-25.3% | 84.39-13.9% | 87.76-0.6% | 90.85-1.3% |
| Total Investments and Advances | 59.28+2466.2% | 79.84+1378.5% | 84.53+259.9% | 2.36-93.0% | 2.31-95.3% | 5.40-92.9% | 23.49-60.7% | 33.59-63.1% |
| Intangible Assets | 34.200.0% | 34.200.0% | 34.200.0% | 34.200.0% | 34.20-11.2% | 34.20-10.9% | 34.20 | 34.20 |
| Other Assets | 0.20-4.8% | 0.21-61.1% | 0.21-60.4% | 0.21-60.4% | 0.21-62.5% | 0.540.0% | 0.53-1.9% | 0.53-1.9% |
| Total Assets | 262.63+7.3% | 287.01+0.8% | 326.55+3.5% | 223.70-36.7% | 244.72-37.0% | 284.69-31.6% | 315.61-9.4% | 353.22-2.1% |
| Short Term Debt Incl. Current Port. of LT Debt | 3.85+2.1% | 4.04-17.4% | 4.08-16.4% | 3.32-31.8% | 3.77+0.3% | 4.89+33.6% | 4.88+120.8% | 4.87+222.5% |
| Accounts Payable | 2.98+13.7% | 4.82+50.2% | 3.15-11.8% | 4.77+54.9% | 2.62+0.8% | 3.21-4.5% | 3.57+4.1% | 3.08+12.4% |
| Other Current Liabilities | 7.22-53.8% | 6.21-9.3% | 6.33+4.6% | 12.13-90.0% | 15.64+16.2% | 6.85-43.6% | 6.05-41.9% | 121.84+796.5% |
| Total Current Liabilities | 14.04-36.3% | 15.07+0.8% | 13.57-6.4% | 20.23-84.4% | 22.03+11.2% | 14.95-22.0% | 14.50-9.8% | 129.78+627.1% |
| Long Term Debt | 33.65-18.3% | 34.63-25.7% | 43.94-8.1% | 40.24-17.8% | 41.19-19.0% | 46.59-11.6% | 47.79+8.0% | 48.96+4.9% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 4.30-1.6% | 4.30-1.6% | 4.30-1.6% | 4.30-1.6% | 4.37+24.9% | 4.37+29.7% | 4.37 | 4.37 |
| Other Liabilities | 0.67-14.1% | 0.67-92.5% | 0.00-100.0% | 0.00-100.0% | 0.78-99.3% | 8.88-92.5% | 8.50-92.3% | 8.74-92.2% |
| Total Liabilities | 52.66-23.0% | 54.66-26.9% | 61.81-17.8% | 64.77-66.2% | 68.37-64.6% | 74.79-61.5% | 75.17-55.9% | 191.85+9.0% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 209.97+19.1% | 232.34+10.7% | 264.74+10.1% | 158.94-1.5% | 176.35-9.9% | 209.90-5.5% | 240.44+35.2% | 161.36-12.7% |
| Total Shareholders Equity | 209.97+19.1% | 232.34+10.7% | 264.74+10.1% | 158.94-1.5% | 176.35-9.9% | 209.90-5.5% | 240.44+35.2% | 161.36-12.7% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 209.97+19.1% | 232.34+10.7% | 264.74+10.1% | 158.94-1.5% | 176.35-9.9% | 209.90-5.5% | 240.44+35.2% | 161.36-12.7% |
| Total Liabilities & Stockholders Equity | 262.63+7.3% | 287.01+0.8% | 326.55+3.5% | 223.70-36.7% | 244.72-37.0% | 284.69-31.6% | 315.61-9.4% | 353.22-2.1% |
| Book Value Per Share per share | 1.16-43.1% | 1.29-46.9% | 1.47-47.3% | 1.82-3.2% | 2.04-11.7% | 2.43-7.6% | 2.79+1.8% | 1.88-38.6% |
| Tangible Book Value Per Share per share | 0.97-40.9% | 1.10-46.1% | 1.28-46.4% | 1.43-3.4% | 1.64-11.4% | 2.04-6.0% | 2.39-12.8% | 1.48-51.6% |
| Full-Time Employees people | - | - | - | 78-48.0% | - | - | - | 150-9.1% |
| Price to Book Ratio ratio | 1.27 | 1.67 | 1.24 | 0.49 | 0.20 | 0.20 | 0.25 | 0.44 |
| Return on Assets % | -38.96 | -38.41 | -33.57 | -3.32 | -8.36 | -6.64 | -6.61 | -35.46 |
| Return on Equity % | -51.16 | -49.65 | -42.67 | -5.98 | -14.23 | -10.78 | -10.49 | -73.14 |
| Return on Invested Capital % | -9.63 | -12.94 | -7.01 | -9.63 | -15.82 | -12.69 | 26.56 | -17.15 |
| Quick Ratio ratio | 8.74 | 8.28 | 10.25 | 5.97 | 6.25 | 10.72 | 11.70 | 1.50 |
| Current Ratio ratio | 8.74 | 8.28 | 10.25 | 5.97 | 6.25 | 10.72 | 11.70 | 1.50 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -23.45 | -34.55 | -21.64-128.3% | -19.17 | -34.43 | -32.54 | 76.56 | -36.07 |
| Depreciation | 2.19-30.0% | 2.62-18.1% | 3.00-6.8% | 3.55+6.9% | 3.13-5.2% | 3.20-7.5% | 3.22-0.3% | 3.32-40.2% |
| Other Funds (Non Cash) | 1.49-77.1% | 11.41+365.7% | -0.17-109.4% | -3.54-160.7% | 6.51+174.7% | 2.45 | 1.81-50.1% | 5.83-44.6% |
| Funds from Operations | -19.78 | -20.52 | -18.81-123.1% | -19.23 | -24.79 | -26.89 | 81.59 | -26.05 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -2.45 | 0.69 | -6.43 | 3.16+72.7% | -0.80 | -0.70-198.6% | -116.21 | 1.83 |
| Cash from Operating Activities | -22.23 | -19.83 | -25.24 | -16.08 | -25.58 | -27.59 | -34.62 | -24.22 |
| Capital Expenditures | -0.54 | -0.69 | -0.58 | 0.14 | -0.20-125.0% | -0.32 | -0.47 | -0.15 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.06 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | 0.00 | -0.02 |
| Purchase or Sale of Investments | 18.06-27.4% | 18.40-44.0% | -112.03-494.3% | 22.22-27.8% | 24.87-35.2% | 32.86 | 28.41+135.2% | 30.78+57.2% |
| Purchase of Investments | -1.31 | -15.97 | -140.69 | -15.60 | -11.02 | -9.67 | -14.88 | -17.40 |
| Sale Or Maturity of Investments | 19.37-46.0% | 34.37-19.2% | 28.66-33.8% | 37.82-21.5% | 35.89-30.4% | 42.52+42.4% | 43.29-8.2% | 48.18+64.6% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 17.53-28.9% | 17.77-45.4% | -112.61-503.2% | 22.36-27.0% | 24.67-37.1% | 32.54 | 27.93+142.0% | 30.61+64.6% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.08 | 0.31 | 126.62+105416.7% | 0.05-99.7% | 0.00-100.0% | 0.00-100.0% | 0.12-67.6% | 17.23 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.08 | 0.31 | 126.62+105416.7% | 0.05-99.7% | 0.00-100.0% | 0.00-100.0% | 0.12-67.6% | 17.23 |
| Proceedsfrom Stock Options | 0.00 | -0.04 | 126.42 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 17.09 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | -17.83 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.08 | 0.31 | 126.62+105416.7% | 0.05 | 0.00-100.0% | 0.00-100.0% | 0.12-99.3% | -0.60 |
| Net Change in Cash | -4.63 | -1.76-135.6% | -11.23 | 6.34+9.7% | -0.91-108.2% | 4.95 | -6.57 | 5.78 |
| Free Cash Flow | -22.76 | -20.53 | -25.83 | -15.94 | -25.78 | -27.91 | -35.10 | -24.38 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Biological Products, (No Diagnostic Substances) | 6.59 | 109.16 | +1556.8% | 100.0% |
| Total | 6.59 | 109.16 | +1556.8% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 6.59 | 109.16 | +1556.8% | 100.0% |
| Total | 6.59 | 109.16 | +1556.8% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 26.04% | 32.0M | 123.0M | 672.20K |
| 2026-10-15 | 23.69% | 29.1M | 123.0M | 624.36K |
| 2026-09-30 | 23.77% | 29.2M | 122.9M | 665.97K |
| 2026-09-15 | 23.88% | 29.4M | 122.9M | 1.06M |
| 2026-08-31 | 24.07% | 29.5M | 122.7M | 1.15M |
| 2026-08-14 | 23.94% | 29.4M | 122.7M | 1.24M |
| 2026-07-31 | 24.41% | 29.8M | 122.1M | 1.25M |
| 2026-07-15 | 23.24% | 28.4M | 122.1M | 1.28M |
| 2026-06-30 | 19.20% | 23.5M | 122.1M | 1.29M |
| 2026-06-15 | 12.62% | 15.4M | 122.1M | 1.13M |
| 2026-05-29 | 10.20% | 12.5M | 122.3M | 1.20M |
| 2026-05-15 | 10.61% | 12.2M | 115.1M | 1.18M |
| 2026-04-30 | 10.50% | 12.0M | 114.7M | 1.25M |
| 2026-04-15 | 9.58% | 11.0M | 114.5M | 1.42M |
| 2026-03-31 | 9.00% | 10.3M | 114.3M | 1.86M |
| 2026-03-13 | 7.55% | 8.6M | 114.3M | 1.86M |
| 2026-02-27 | 5.54% | 6.3M | 114.2M | 1.75M |
| 2026-02-13 | 4.15% | 4.7M | 114.2M | 1.79M |
| 2026-01-30 | 6.30% | 3.4M | 53.8M | 1.93M |
| 2026-01-15 | 1.49% | 0.8M | 54.3M | 1.76M |
Option chain
Expiry 2026-11-20 · underlying 1.63, quoted 12 Nov 15:59 ET · ATM 1.50
Option quotes 11 Nov 10:11 ET. A date on a row is older than the last session (12 Nov). 14 rows.
Implied move 46.01% into expiry (call 0.250 + put 0.500 = 0.750 on 1.63)
Put/call open interest 0.00 (0 puts / 345 calls) · Put/call volume — no calls
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call 11 Nov | 0.50 | ITM | 0.75 | 1.75 | 1.17 | 0.00 | - | 45 | 0 | 0 | 0.957 | -0.009 | 0.000 |
| put 1 Jan | OTM | 0.00 | 0.05 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.043 | -0.009 | 0.000 | |
| call 11 Nov | 1.00 | ITM | 0.20 | 1.20 | 0.75 | 0.00 | 1380.7% +855.2 | 75 | 0 | 0 | 0.848 | -0.019 | 0.001 |
| put 1 Jan | OTM | 0.00 | 0.15 | 0.00 | 0.00 | 522.5% 0.0 | 0 | 0 | 0 | -0.138 | -0.018 | 0.001 | |
| call 20 Oct | 1.50 | ATM | 0.00 | 0.50 | 0.35 | 0.00 | 481.5% -792.5 | 166 | 0 | 0 | 0.836 | -0.048 | 0.001 |
| put 1 Jan | ATM | 0.00 | 1.00 | 0.00 | 0.00 | 1355.0% +37.0 | 0 | 0 | 0 | -0.153 | -0.048 | 0.001 | |
| call 6 Nov | 2.00 | OTM | 0.00 | 1.00 | 0.01 | 0.00 | 638.8% 0.0 | 57 | 0 | 0 | 0.606 | -0.038 | 0.001 |
| put 1 Jan | ITM | 0.05 | 1.05 | 0.00 | 0.00 | 809.0% +194.9 | 0 | 0 | 0 | -0.395 | -0.036 | 0.001 | |
| call 21 Sep | 2.50 | OTM | 0.00 | 1.00 | 0.15 | 0.00 | 330.9% 0.0 | 2 | 0 | 0 | 0.262 | -0.016 | 0.001 |
| put 1 Jan | ITM | 0.35 | 1.35 | 0.00 | 0.00 | 801.4% +470.5 | 0 | 0 | 0 | -0.738 | -0.016 | 0.001 | |
| call 1 Jan | 5.00 | OTM | 0.00 | 0.05 | 0.00 | 0.00 | 437.7% 0.0 | 0 | 0 | 0 | 0.113 | -0.013 | 0.001 |
| put 1 Jan | ITM | 1.00 | 5.50 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.885 | -0.014 | 0.000 | |
| call 1 Jan | 7.50 | OTM | 0.00 | 2.55 | 0.00 | 0.00 | - | 0 | 0 | 0 | 0.101 | -0.016 | 0.000 |
| put 1 Jan | ITM | 3.50 | 8.00 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.900 | -0.015 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | 8-K | Current report | 2026-11-12 | SEC |
| 2026-11-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-03 | SEC |
| 2026-11-03 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-10-02 | 8-K | Current report | 2026-10-02 | SEC |
| 2026-09-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-11 | SEC |
| 2026-09-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-14 | SEC |
| 2026-09-14 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-14 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-09-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-09 | SEC |
| 2026-09-10 | 3 | Initial statement of beneficial ownership of securities | 2026-09-09 | SEC |
| 2026-09-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-04 | SEC |
| 2026-09-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-08 | SEC |
| 2026-09-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-08 | SEC |
| 2026-09-09 | 8-K | Current report | 2026-09-09 | SEC |
| 2026-09-08 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-14 | SEC |
| 2026-08-12 | 8-K | Current report | 2026-08-12 | SEC |
| 2026-08-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-03 | SEC |
| 2026-06-16 | 8-K | Current report | 2026-06-15 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-15 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-12 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
| 2026-06-12 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-11 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 404 | 1 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 9.81K | 4 |
| 2026-08 | 0 | 0 | 544 | 1 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 11.09K | 4 |
| 2026-05 | 0 | 0 | 618 | 1 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 44.85K | 3 |
| 2026-02 | 0 | 0 | 589 | 1 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 79.60K | 2 | 417 | 2 |
| 2025-11 | 17.33K | 1 | 17.64K | 3 |
Institutional holders
| Manager | % owned |
|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.84% |
| TCG Crossover Management, LLC | 9.84% |
| Versant Venture Management, LLC | 6.75% |
| Deep Track Capital, LP | 5.25% |
| Commodore Capital LP | 4.82% |
| RTW INVESTMENTS, LP | 4.82% |
| Venrock Adviser, LLC | 4.82% |
| BlackRock, Inc. | 4.49% |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.16% |
| BALYASNY ASSET MANAGEMENT L.P. | 3.06% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.41% |
| iShares Russell 2000 ETF | 1.61% |
| Fidelity Small Cap Index Fund | 0.74% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.68% |
| iShares Russell 2000 Value ETF | 0.61% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.39% |
| Small Cap Value Fund | 0.30% |
| Fidelity Extended Market Index Fund | 0.29% |
| iShares Micro-Cap ETF | 0.23% |
| Schwab Small-Cap Index Fund | 0.17% |
OakChart. IPSC. Cached 15 minutes. Terms